Smith & Nephew reported consensus beating Q2 21 sales growth of 40.3%, thanks to a strong recovery in Orthopaedics (+43.4%) and ‘sports medicine & ENT’ (+50.9%). Regionally, growth was driven by the established markets (+46.8%).
For H1, revenue growth came in at 27.8% with a trading margin of 17.6% (+920bps, 40bps ahead of consensus). Guidance of 10%-13% top-line growth and an 18%-19% trading margin was re-iterated.
Following the broadly in-line performance, we do not expect any significant ch ....
29 Jul 2021
Q2 21: Marginal beat not good enough
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 21: Marginal beat not good enough
Smith & Nephew plc (SN:LON) | 1,052 -110.4 (-1.0%) | Mkt Cap: 9,193m
- Published:
29 Jul 2021 -
Author:
Virendra Chauhan -
Pages:
4
Smith & Nephew reported consensus beating Q2 21 sales growth of 40.3%, thanks to a strong recovery in Orthopaedics (+43.4%) and ‘sports medicine & ENT’ (+50.9%). Regionally, growth was driven by the established markets (+46.8%).
For H1, revenue growth came in at 27.8% with a trading margin of 17.6% (+920bps, 40bps ahead of consensus). Guidance of 10%-13% top-line growth and an 18%-19% trading margin was re-iterated.
Following the broadly in-line performance, we do not expect any significant ch ....